Qingdao Central Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Chemoimmunotherapy Plus Residual Lesion Irradiation for the Treatment of Extensive Stage Small-cell Lung Cancer

Recruiting

Conditions: Small-cell Lung Cancer
Radiation
Residual Tumor

Interventions: Radiation: residual tumor irradiation

First Posted Date: 2024-07-23

Last Posted Date: 2024-07-23

Lead Sponsor: Qingdao Central Hospital

Target Recruit Count: 70

Registration Number: NCT06514118

Locations: 🇨🇳
Qingdao Central Hospital, Qingdao, Shandong, China

Nutrition Impact on Immunotherapy of Cancer

Phase 3

Recruiting

Conditions: Nutrition Disorders
Cancer
Survival, Prosthesis
Immunotherapy

Interventions: Drug: Megestrol Acetate and olanzapine
Drug: Starch powder 50 mg

First Posted Date: 2024-07-15

Last Posted Date: 2024-07-15

Lead Sponsor: Qingdao Central Hospital

Target Recruit Count: 300

Registration Number: NCT06500234

Locations: 🇨🇳
Qingdao Central Hospital, Qingdao, Shandong, China

Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer

Phase 2

Recruiting

Conditions: Metastatic Esophageal Squamous Cell Carcinoma

Interventions: Drug: TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1 inhibitors（Sintilimab）

First Posted Date: 2023-11-18

Last Posted Date: 2024-07-24

Lead Sponsor: Qingdao Central Hospital

Target Recruit Count: 90

Registration Number: NCT06138028

Locations: 🇨🇳
Qingdao Central Hospital, Qingdao Cancer Hospital, Qingdao, Shandong, China
🇨🇳
Qingdao Central Hospital, Qingdao, Shandong, China

Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical Trial

Phase 2

Conditions: Overall Survival

Interventions: Drug: Rituximab + zanubrutinib + lenalidomide

First Posted Date: 2022-05-26

Last Posted Date: 2022-05-26

Lead Sponsor: Qingdao Central Hospital

Target Recruit Count: 20

Registration Number: NCT05392257

Locations: 🇨🇳
Qingdao central Hospital, Qingdao, Shandong, China

Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer

Phase 2

Recruiting

Conditions: PFS

Interventions: Drug: afatinib

First Posted Date: 2022-03-04

Last Posted Date: 2023-03-29

Lead Sponsor: Qingdao Central Hospital

Target Recruit Count: 30

Registration Number: NCT05267288

Locations: 🇨🇳
Qingdao Central Hospital, Qingdao, China

Chemotherapy Combines With Bevacizumab and PD-1 Inhibitor in Non-squamous NSCLC

Phase 2

Recruiting

Conditions: PFS
OS

Interventions: Drug: PD-1 inhibitor, Bevacizumab, Carboplatin, Cisplatin, Pemtrexed

First Posted Date: 2022-03-04

Last Posted Date: 2023-03-29

Lead Sponsor: Qingdao Central Hospital

Target Recruit Count: 117

Registration Number: NCT05267366

Locations: 🇨🇳
Qingdao central Hospital, Qingdao, Shandong, China

Anlotinib Plus PD-1 Inhibitor as 2nd-line Threapy in Patients With Metastatic Pancreatic Cancer

Phase 2

Recruiting

Conditions: Overall Survival

Interventions: Drug: Anlotinib, PD-1 inhibitor

First Posted Date: 2022-02-01

Last Posted Date: 2023-03-29

Lead Sponsor: Qingdao Central Hospital

Target Recruit Count: 20

Registration Number: NCT05218629

Locations: 🇨🇳
Qingdao central Hospital, Qingdao, Shandong, China

Colchicine Use for Primary Prevention of Coronary Artery Disease

Phase 3

Not yet recruiting

Conditions: Coronary Artery Disease

Interventions: Drug: Placebo
Drug: Colchicine

First Posted Date: 2022-01-03

Last Posted Date: 2022-03-21

Lead Sponsor: Qingdao Central Hospital

Target Recruit Count: 6792

Registration Number: NCT05175274

Locations: 🇨🇳
Mengmei Li, Qingdao, Shandong, China

Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer

Phase 3

Recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: osimertinib oral and bevazizumab intravenously

First Posted Date: 2021-11-02

Last Posted Date: 2023-03-29

Lead Sponsor: Qingdao Central Hospital

Target Recruit Count: 60

Registration Number: NCT05104281

Locations: 🇨🇳
Qingdao Central Hospital, Qingdao Cancer Hospital, Qingdao, Shandong, China

Sacubitril/Valsartan Versus Valsartan for Hypertensive Patients With Acute Myocardial Infarction

Phase 4

Conditions: Myocardial Infarction
Hypertension

Interventions: Drug: Valsartan 80mg/Tab
Drug: Sacubitril/Valsartan 49/51mg/Tab

First Posted Date: 2021-09-29

Last Posted Date: 2021-09-29

Lead Sponsor: Qingdao Central Hospital

Target Recruit Count: 200

Registration Number: NCT05060588

Locations: 🇨🇳
Mengmei Li, Qingdao, Shandong, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy